Application

KRAZATI

Mirati Therapeutics, Inc.

Trademark/Service Mark Application, Principal Register

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97541713
Filing Date: 08/09/2022

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 97541713
MARK INFORMATION
*MARK \\TICRS\EXPORT18\IMAGEOUT 18\975\417\97541713\xml1 \ APP0002.JPG
SPECIAL FORM YES
USPTO-GENERATED IMAGE NO
LITERAL ELEMENT KRAZATI
COLOR MARK YES
COLOR(S) CLAIMED
(If applicable)
The color(s) white, blue, and green is/are claimed as a feature of the mark.
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of the stylized term "KRAZATI", with the "K" in white and green and the remaining letters in white, all on a blue background.
PIXEL COUNT ACCEPTABLE NO
PIXEL COUNT 1079 x 250
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Mirati Therapeutics, Inc.
*MAILING ADDRESS 3545 Cray Court
*CITY San Diego
*STATE
(Required for U.S. applicants)
California
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
92121
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 005 
*IDENTIFICATION pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
FILING BASIS SECTION 1(b)
ATTORNEY INFORMATION
NAME Eric R. Moran
ATTORNEY DOCKET NUMBER 22-1326-US
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME McDonnell Boehnen Hulbert & Berghoff LLP
INTERNAL ADDRESS 31st Floor
STREET 300 South Wacker Drive
CITY Chicago
STATE Illinois
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 60606
PHONE 312-913-0001 x3302
FAX 312-913-0002
EMAIL ADDRESS docketing@mbhb.com
OTHER APPOINTED ATTORNEY All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP
CORRESPONDENCE INFORMATION
NAME Eric R. Moran
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE docketing@mbhb.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) moran@mbhb.com; potempam@mbhb.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 1
APPLICATION FOR REGISTRATION PER CLASS 350
*TOTAL FEES DUE 350
*TOTAL FEES PAID 350
SIGNATURE INFORMATION
SIGNATURE /Eric R. Moran/
SIGNATORY'S NAME Eric R. Moran
SIGNATORY'S POSITION Attorney of record, Illinois bar member
SIGNATORY'S PHONE NUMBER 312-913-3302
DATE SIGNED 08/09/2022
SIGNATURE METHOD Signed directly within the form



PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Trademark/Service Mark Application, Principal Register

Serial Number: 97541713
Filing Date: 08/09/2022

To the Commissioner for Trademarks:

MARK: KRAZATI (stylized and/or with design, see mark)
The literal element of the mark consists of KRAZATI. The color(s) white, blue, and green is/are claimed as a feature of the mark. The mark consists of the stylized term "KRAZATI", with the "K" in white and green and the remaining letters in white, all on a blue background.
The applicant, Mirati Therapeutics, Inc., a corporation of Delaware, having an address of
      3545 Cray Court
      San Diego, California 92121
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The owner's/holder's proposed attorney information: Eric R. Moran. Other appointed attorneys are All other attorneys at McDonnell Boehnen Hulbert & Berghoff LLP. Eric R. Moran of McDonnell Boehnen Hulbert & Berghoff LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      31st Floor
      300 South Wacker Drive
      Chicago, Illinois 60606
      United States
      312-913-0001 x3302(phone)
      312-913-0002(fax)
      docketing@mbhb.com
The docket/reference number is 22-1326-US.
Eric R. Moran submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      Eric R. Moran
       PRIMARY EMAIL FOR CORRESPONDENCE: docketing@mbhb.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): moran@mbhb.com; potempam@mbhb.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

Declaration Signature

Signature: /Eric R. Moran/   Date: 08/09/2022
Signatory's Name: Eric R. Moran
Signatory's Position: Attorney of record, Illinois bar member
Signatory's Phone Number: 312-913-3302
Signature method: Signed directly within the form
Payment Sale Number: 97541713
Payment Accounting Date: 08/09/2022

Serial Number: 97541713
Internet Transmission Date: Tue Aug 09 18:10:09 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.XXX.XX-2022080918100972
8828-97541713-82017717f32f6d41a675dfe2ab
9d720af9827ff8a51e4f036f3481c2ffc26822d7
2-CC-10051914-20220809180502936270

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed